Clinical trial
5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus…
NCT00433927 · PD Dr. med. Volker Heinemann, Other · Unknown status
Key facts
| NCT number | NCT00433927 |
|---|---|
| Title | 5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC) |
| Official title | Multicenter Randomized Trial Evaluating FOLFIRI Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment of Metastatic Colorectal Cancer. |
| Lead sponsor | PD Dr. med. Volker Heinemann, Other |
| Collaborators | Merck KGaA, Darmstadt, Germany Industry |
| Status | Unknown status |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Neoplasm Metastasis, Colorectal Cancer |
| Intervention type | Drug |
| Interventions | 5-FU, folinic acid, irinotecan, cetuximab, bevacizumab |
| Enrollment | 568 |
| Start date | Jan 1, 2007 |
| Primary completion | Apr 1, 2014 |
| Completion | Dec 1, 2016 |
| First posted | Feb 12, 2007 |
| Last update posted | Mar 14, 2014 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: